Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity (Details Narrative)

v3.23.3
Stockholders’ Equity (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 22, 2023
Sep. 22, 2023
Sep. 07, 2023
Jan. 27, 2023
Jan. 26, 2023
Jan. 23, 2023
Jan. 31, 2020
Sep. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]                            
Reverse stock split   1-for-20 reverse stock split                        
Common shares issued to round-up fractional shares 40,197                          
Preferred stock, shares authorized               10,000,000     10,000,000   10,000,000  
Preferred stock, par value               $ 0.001     $ 0.001   $ 0.001  
Preferred stock, shares issued               316     316   465  
Preferred stock, shares outstanding               316     316   465  
Options exercise price                     $ 3.06      
Number of Options, Granted                     21,704   24,374  
Allocation share based compensation expense               $ 84,078   $ 275,418 $ 447,417 $ 613,833    
Number of Options Outstanding, Beginning Balance                 89,953   89,953 69,795 69,795  
Weighted Average Exercise Price Outstanding, Beginning Balance                 $ 75.20   $ 75.20 $ 84.80 $ 84.80  
Weighted Average Remaining Contractual Life Years, Outstanding Balance                     2 years 11 months 15 days   3 years 3 months 18 days 3 years 10 months 20 days
Aggregate Intrinsic Value, Outstanding Beginning Balance                      
Weighted Average Exercise Price, Granted                     $ 11.60   $ 50.00  
Weighted Average Remaining Contractual Life Years, Granted                     4 years 3 months 25 days   4 years 5 months 4 days  
Aggregate Intrinsic Value, Granted                          
Number of Options, Exercised                     0   0  
Weighted Average Exercise Price, Exercised                        
Aggregate Intrinsic Value, Exercised                        
Number of Options, Forfeited or cancelled                     (20,930)   (4,216)  
Weighted Average Exercise Price, Forfeited or cancelled                     $ 68.59   $ 87.80  
Aggregate Intrinsic Value, Forfeited or cancelled                        
Number of Options Outstanding, Ending Balance               90,727     90,727   89,953 69,795
Weighted Average Exercise Price Outstanding, Ending Balance               $ 61.58     $ 61.58   $ 75.20 $ 84.80
Aggregate Intrinsic Value Outstanding, Ending Balance                      
Number of Options, Unvested               15,876     15,876      
Weighted Average Exercise Price, Unvested               $ 37.11     $ 37.11      
Weighted Average Remaining Contractual Life Years, Unvested                     3 years 9 months 29 days      
Aggregate Intrinsic Value, Options Unvested                        
Number of Options, Vested               74,851     74,851      
Weighted Average Exercise Price, Vested               $ 66.76     $ 66.76      
Weighted Average Remaining Contractual Life Years, Vested                     2 years 9 months 10 days      
Aggregate Intrinsic Value, Options Vested                        
Unrecognized stock-based compensation expense, stock option               278,132     $ 278,132      
Weighted average remaining recognition period                     1 year 3 months 3 days      
Directors [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Vesting percentage                     75.00%      
Directors [Member] | December 31, 2022 [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Vesting percentage                     25.00%      
19 Employees [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Vesting percentage         50.00%                  
Number of Options, Granted         19,065                  
Option strike price         $ 11.60                  
2020 Stock Appreciation Rights Plan [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Options exercise price                     $ 3.06      
Unrecognized share based compensation cost               $ 396,579     $ 396,579      
Weighted average remaining recognition period                     1 year 6 months 3 days      
Employee Retention Agreements [Member] | 2020 Stock Appreciation Rights Plan [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Options exercise price         $ 11.60                  
Series E Convertible Preferred Stock [Member] | Other Securities Purchase Agreement [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Share issued and sold during period, shares                     333      
Conversion of stock, shares converted                     2,428      
Dividend rate                     9.00%      
Series D Preferred Stock [Member] | Institutional Securities Purchase Agreement [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Share issued and sold during period, shares             1,640              
Common stock issued during period       13,541                    
Preferred stock, par value             $ 1,000              
Preferred stock, shares outstanding       132       0     0      
Dividend rate             9.00%              
Conversion price per share               $ 6.00     $ 6.00      
Series E Preferred Stock [Member] | Institutional Securities Purchase Agreement [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Common stock issued during period           155                
Preferred stock, par value               $ 1,000     $ 1,000      
Preferred stock, shares outstanding           17   316     316      
Number of stock issued converted during period, shares                     3,069      
Common Stock [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Common stock issued during period               72,721     72,721      
Number of stock issued converted during period, shares                     11,501      
Common Stock [Member] | Series D Convertible Preferred Stock [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Conversion of stock, shares converted                 132          
Number of shares as in-kind payment, shares                 2,161          
Common Stock [Member] | Series E Convertible Preferred Stock [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Conversion of stock, shares converted                 17          
Number of shares as in-kind payment, shares                 33          
At-The-Market Issuance Sales Agreement [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Common stock issued during period     364,555                      
At-The-Market Issuance Sales Agreement [Member] | Common Stock [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Share issued and sold during period, shares               72,721            
Net proceeds               $ 364,555            
Private Placement [Member] | Purchase Agreement [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Warrants to purchase shares of common stock         2,620                  
Private Placement [Member] | Common Stock [Member] | Series D Convertible Preferred Stock [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Common stock issued during period                 11,380          
Private Placement [Member] | Common Stock [Member] | Series E Convertible Preferred Stock [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Common stock issued during period                 122